According to PharmaTimes, the European Commission has granted marketing authorisation for dronedarone (Multaq®), indicated for adult clinically stable patients with a history of, or current non-permanent atrial fibrillation to prevent recurrence of AF or to lower ventricular rate.

The first EU launches of dronedarone are expected to take place in the UK and Germany in January.  It is already approved in the USA, Canada, Switzerland and Brazil.